SCHEMBL3701494

SCHEMBL3701494

CNC(=O)c1cc(S(=O)(=O)c2cccc(OC)c2)n(-c2ccccc2C)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC16A3 O15427 1/20 0.40
SLC16A1 P53985 1/20 0.40
PTGDR2 Q9Y5Y4 1/20 0.40
ALDH1A1 P00352 4/20 0.39
LMNA P02545 2/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.39
HIF1A Q16665 1/20 0.39
MALT1 Q9UDY8 1/20 0.39
ADORA1 P30542 3/20 0.38
FFAR4 Q5NUL3 1/20 0.38
BAZ2B Q9UIF8 1/20 0.38
KAT6A Q92794 2/20 0.38
PLK1 P53350 1/20 0.38
MTNR1B P49286 1/20 0.38
MME P08473 1/20 0.37
CYP3A4 P08684 1/20 0.37
CTSA P10619 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3700747 0.89 TSHR (0.46) SLC16A3SLC16A1ALDH1A1LMNAMEN1
SCHEMBL3689795 0.85 TP53 (0.45) SLC16A3SLC16A1ALDH1A1MEN1KMT2A
Hydrochloric Acid SCHEMBL3701972 0.80 SLC16A3 (0.42) SLC16A3SLC16A1PTGDR2ALDH1A1LMNA
SCHEMBL3694226 0.80 TSHR (0.48) SLC16A3SLC16A1PTGDR2ALDH1A1LMNA
SCHEMBL3706780 0.80 ALDH1A1 (0.40) ALDH1A1MEN1KMT2AMAPTMALT1
SCHEMBL3704610 0.78 MALT1 (0.39) ALDH1A1LMNAMEN1KMT2AMAPT
SCHEMBL3692589 0.76 NPSR1 (0.45) SLC16A3SLC16A1ALDH1A1LMNAKMT2A
SCHEMBL3695120 0.76 CTSA (0.42) MEN1KMT2AMALT1BAZ2BMME
SCHEMBL3694089 0.72 NFE2L2 (0.41) ALDH1A1MAPTMTNR1B
SCHEMBL3695931 0.71 MALT1 (0.41) LMNAMEN1KMT2AHPGDMALT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2190822-B1 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS TAKEDA PHARMACEUTICAL (JP) 2014-12-31 EP disclosed
EP-2190822-A2 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2010-06-02 EP disclosed
WO-2009041705-A9 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS TAKEDA PHARMACEUTICAL (JP) 2009-08-13 WO disclosed
US-20090156642-A1 5-Membered heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-18 US disclosed
WO-2009041705-A2 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156642-A1 5-Membered heterocyclic compound CEL, PGA5, COG5 SLC16A3 2809/4885SLC16A1 2925/4885PTGDR2 1159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.